Skip to main content

February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology

Multiple Myeloma, Oncology
Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma
Phoebe Starr
Read More
Lymphoma
Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma
Chase Doyle
Read More
Leukemia, Oncology
Venetoclax plus Intensive Chemotherapy Shows Promising Results in All Patients with Acute Myeloid Leukemia
Chase Doyle
Read More
Leukemia, Oncology
All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy
Wayne Kuznar
Read More
Leukemia, Oncology
Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia
Wayne Kuznar
Read More
Leukemia, Oncology
First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL
Wayne Kuznar
Read More
Leukemia, Oncology
Zanubrutinib, Next-Generation BTK, Leads to Impressive Responses in Patients with CLL or SLL
Phoebe Starr
Read More
FDA Approvals
Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy May Prevent Cytokine Release Syndrome
Wayne Kuznar
Read More
FDA Approvals, Prostate Cancer
Xtandi Now Approved for Metastatic Castration-Sensitive Prostate Cancer
Read More
FDA Approvals
Keytruda Indicated for BCG-Unresponsive High-Risk, Non–Muscle Invasive Bladder Cancer
Read More
Page 1 of 3
Results 1 - 10 of 26